Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Follow-Up Questions
Hiệu suất giá của cổ phiếu PRNAF như thế nào?
Giá hiện tại của PRNAF là $0, đã decreased 0% trong ngày giao dịch cuối cùng.
Chủ đề kinh doanh chính hoặc ngành của Alterity Therapeutics Ltd là gì?
Alterity Therapeutics Ltd thuộc ngành Biotechnology và lĩnh vực là Health Care
Vốn hóa thị trường của Alterity Therapeutics Ltd là bao nhiêu?
Vốn hóa thị trường hiện tại của Alterity Therapeutics Ltd là $0
